Stratos Wealth Partners LTD. Decreases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Stratos Wealth Partners LTD. lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 26.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 84,014 shares of the biopharmaceutical company’s stock after selling 30,504 shares during the period. Stratos Wealth Partners LTD.’s holdings in Gilead Sciences were worth $7,760,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. nVerses Capital LLC purchased a new position in Gilead Sciences during the 3rd quarter valued at about $25,000. HHM Wealth Advisors LLC increased its stake in shares of Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 154 shares during the period. Valued Wealth Advisors LLC raised its holdings in shares of Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 161 shares in the last quarter. Decker Retirement Planning Inc. purchased a new stake in Gilead Sciences in the fourth quarter worth $29,000. Finally, Crews Bank & Trust purchased a new position in Gilead Sciences during the 4th quarter valued at $31,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ GILD opened at $99.65 on Thursday. The stock has a market capitalization of $124.19 billion, a price-to-earnings ratio of 1,107.22, a PEG ratio of 1.37 and a beta of 0.18. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $100.51. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The business’s fifty day moving average price is $92.71 and its 200-day moving average price is $86.32.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same period in the previous year, the company posted $2.29 EPS. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. On average, equities analysts predict that Gilead Sciences, Inc. will post 4.34 earnings per share for the current year.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 164,211 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the sale, the insider now owns 80,801 shares in the company, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 572,824 shares of company stock valued at $53,611,715. 0.29% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on GILD shares. Piper Sandler raised their target price on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Morgan Stanley raised Gilead Sciences from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $87.00 to $113.00 in a research report on Friday, January 10th. Mizuho increased their target price on Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. Oppenheimer lifted their price target on Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. Finally, Leerink Partners upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $74.00 to $96.00 in a report on Monday, October 21st. Eleven investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and an average price target of $98.39.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.